Intravitreal Panitumumab for Prevention of Myopic Axial Elongation in Highly Myopic Adult Eyes with Myopic Macular Degeneratio
- Conditions
- Myopic ophthalmopathy
- Registration Number
- DRKS00027302
- Lead Sponsor
- fa Eye Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Age of 40+ years,
- Axial length =26.5mm;
- Myopic macular degeneration (category 3 (patchy atrophy) or higher).
- Clear optic media to allow imaging of the macula and optic nerve head;
- Progression of myopic maculopathy (increase in diffuse chorioretinal atrophy, enlargement of patchy atrophies, increase in the category of myopic macular degeneration, enlargement in parapapillary gamma/delta zone, increase in axial length, increase in myopic refractive error (after exclusion of lentogenic myopization), or myopia-associated reduction in best corrected visual acuity
- Previous vitreoretinal or retinal surgeries (except for peripheral retinal laser coagulation)
- Previous intravitreal medical therapy with vascular endothelial growth factor (VEGF) inhibitors within the last three months before inclusion into the study;
- Active subretinal choroidal neovascularization;
- Subretinal or intraretinal edema in the macula;
- Pregnancy;
- Lack of reliable contraception unless menopause has occurred;
- Known intolerance or hypersensitivity against panitumumab (Vectibix®) or its ingredients;
- Participation in another clinical trial (parallel or within a cooling off period of a previous trial;
- Missing possibility to understand and sign a written informed consent;
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ocular axial length
- Secondary Outcome Measures
Name Time Method Visual acuity, morphology of the macula and optic nerve head